Adverse events of sorafenib in hepatocellular carcinoma treatment

Area of Science:

• Hepatocellular Carcinoma (HCC) research
• Molecular targeted therapy
• Cancer treatment adverse events

Background:

• Sorafenib is an FDA-approved oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC).
• It targets angiogenesis and tumor cell proliferation pathways, including VEGFR, PDGFR, RAF, and MEK.
• Sorafenib has been the standard of care for advanced HCC for over a decade, particularly for patients ineligible for other therapies.

Purpose of the Study:

• To review the mechanisms underlying sorafenib-associated adverse events in HCC treatment.
• To discuss effective management strategies for these toxicities.

Main Methods:

• Literature review of sorafenib's mechanism of action and known toxicities.
• Analysis of clinical data regarding sorafenib-induced adverse events.
• Synthesis of current management guidelines for sorafenib toxicities.

Main Results:

• Sorafenib offers limited survival benefit (less than 3 months) in advanced HCC.
• Approximately 50% of patients experience clinically significant toxicities.
• These toxicities often necessitate dose reduction or treatment discontinuation.

Conclusions:

• Understanding the mechanisms of sorafenib toxicity is crucial for patient management.
• Effective management strategies are essential to maintain treatment adherence and improve patient outcomes in advanced HCC.
• Further research into managing sorafenib-induced adverse events is warranted.